Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.
暂无分享,去创建一个
[1] M. Caminati,et al. Immune Mechanisms of Allergen-Specific Immunotherapy , 2012 .
[2] C. Czerkinsky,et al. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. , 2012, Current topics in microbiology and immunology.
[3] M. Maddaloni,et al. Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits , 2011, PloS one.
[4] M. Maddaloni,et al. Adenovirus F protein as a delivery vehicle for botulinum B , 2010, BMC Immunology.
[5] Irina A. Kochetkova,et al. IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10 , 2010, The Journal of Immunology.
[6] B. Poulain. [Botulinum neurotoxin]. , 2010, Revue neurologique.
[7] J. Schiller,et al. Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection1 , 2009, The Journal of Immunology.
[8] Leonard A. Smith,et al. Botulinum Neurotoxin Vaccines: Past history and recent developments , 2009, Human vaccines.
[9] Leonard A. Smith. Botulism and vaccines for its prevention. , 2009, Vaccine.
[10] R. Rappuoli,et al. Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.
[11] M Landi,et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children , 2008, Allergy.
[12] Leonard A. Smith,et al. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock , 2008, Journal of immune based therapies and vaccines.
[13] Zhongxia Li,et al. Novel Vaccination Protocol with Two Live Mucosal Vectors Elicits Strong Cell-Mediated Immunity in the Vagina and Protects against Vaginal Virus Challenge1 , 2008, The Journal of Immunology.
[14] C. Czerkinsky,et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection , 2008, Proceedings of the National Academy of Sciences.
[15] Shuang Wang,et al. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. , 2007, Vaccine.
[16] C. Czerkinsky,et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. , 2007, Vaccine.
[17] Eric A. Johnson,et al. Subunit Vaccine against the Seven Serotypes of Botulism , 2007, Infection and Immunity.
[18] H. Malling,et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.
[19] Leonard A. Smith,et al. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. , 2007, Vaccine.
[20] S. Cai,et al. Strategies to design inhibitors of Clostridium botulinum neurotoxins. , 2007, Infectious disorders drug targets.
[21] P. Doherty,et al. Mucosal HIV-1 Pox Virus Prime-Boost Immunization Induces High-Avidity CD8+ T Cells with Regime-Dependent Cytokine/Granzyme B Profiles1 , 2007, The Journal of Immunology.
[22] G. Canonica,et al. Sublingual immunotherapy: update 2006 , 2006, Current opinion in allergy and clinical immunology.
[23] J. Mcghee,et al. Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A1 , 2006, The Journal of Immunology.
[24] S. Durham,et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. , 2006, Journal of Allergy and Clinical Immunology.
[25] G. Canonica,et al. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients , 2006, Allergy.
[26] Leonard A. Smith,et al. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. , 2006, Toxicon : official journal of the International Society on Toxinology.
[27] S. Elliott,et al. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. , 2006, Infectious disease clinics of North America.
[28] P. Moingeon,et al. Immune mechanisms of allergen‐specific sublingual immunotherapy , 2006, Allergy.
[29] M. Lynch,et al. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. , 2005, The Journal of infectious diseases.
[30] J. Bienenstock,et al. Bronchus‐ and nasal‐associated lymphoid tissues , 2005, Immunological reviews.
[31] Jan Holmgren,et al. Mucosal immunity and vaccines , 2005, Nature Medicine.
[32] S. Durham,et al. Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis * , 2005, Allergy.
[33] G. Passalacqua,et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children , 2005, Allergy.
[34] R. Fimmers,et al. Asymptomatic atopy is associated with increased indoleamine 2,3‐dioxygenase activity and interleukin‐10 production during seasonal allergen exposure , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[35] R. Couch. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.
[36] Robert T. Chen,et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.
[37] G. Canonica,et al. Sublingual immunotherapy: an update , 2004, Current opinion in allergy and clinical immunology.
[38] L. Simpson,et al. Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.
[39] E. Kunkel,et al. Plasma-cell homing , 2003, Nature Reviews Immunology.
[40] G. Nabel,et al. Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System , 2003, Journal of Virology.
[41] T. Bieber,et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. , 2003, The Journal of allergy and clinical immunology.
[42] T. Macdonald. The mucosal immune system , 2003, Parasite immunology.
[43] N. Fairweather,et al. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment. , 2003, Vaccine.
[44] D. Pascual,et al. Absence of L-Selectin Delays Mucosal B Cell Responses in Nonintestinal Effector Tissues1 , 2002, The Journal of Immunology.
[45] P. Rufin,et al. Safety of Various Dosage Regimens during Induction of Sublingual Immunotherapy , 2002, International Archives of Allergy and Immunology.
[46] K. Acharya,et al. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. , 2002, Trends in biochemical sciences.
[47] Jie Zhang,et al. Oral Mucosal Drug Delivery , 2002, Clinical pharmacokinetics.
[48] J. Holmgren,et al. Nasal and Vaginal Vaccinations Have Differential Effects on Antibody Responses in Vaginal and Cervical Secretions in Humans , 2001, Infection and Immunity.
[49] N. Walters,et al. Cutting Edge: Dichotomy of Homing Receptor Dependence by Mucosal Effector B Cells: αE Versus L-Selectin1 , 2001, The Journal of Immunology.
[50] N. Walters,et al. Impaired Mucosal Immunity in L-Selectin-Deficient Mice Orally Immunized with a Salmonella Vaccine Vector1 , 2001, The Journal of Immunology.
[51] J. Mcghee,et al. Oral Tolerance Revisited: Prior Oral Tolerization Abrogates Cholera Toxin-Induced Mucosal IgA Responses1 , 2001, The Journal of Immunology.
[52] Gerhard Walzl,et al. Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses1 , 2001, The Journal of Immunology.
[53] A. Frew,et al. Sublingual immunotherapy. , 2008, The New England journal of medicine.
[54] J. Mcghee,et al. Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.
[55] Č. Venclovas,et al. Structure‐based sequence alignment for the β‐trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site , 2000, FEBS letters.
[56] L. Smith,et al. Development of vaccines for prevention of botulism. , 2000, Biochimie.
[57] S. Swaminathan,et al. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B , 2000, Nature Structural Biology.
[58] J. Middlebrook,et al. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. , 2000, Vaccine.
[59] Leonard A. Smith,et al. Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate , 1998, Infection and Immunity.
[60] D. Swerdlow,et al. Botulism in the United States: A Clinical and Epidemiologic Review , 1998, Annals of Internal Medicine.
[61] W. C. Stewart,et al. Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. , 1998, Archives of internal medicine.
[62] A. B. Maksymowych,et al. Induction of an immune response by oral administration of recombinant botulinum toxin , 1997, Infection and immunity.
[63] Cleary Jf. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. , 1997 .
[64] J. Holmgren,et al. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina , 1997, Infection and immunity.
[65] E. Butcher,et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.
[66] J. Cleary. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. , 1997, Seminars in oncology.
[67] B. Spangler,et al. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. , 1992, Microbiological reviews.
[68] C. Hatheway,et al. Toxigenic clostridia , 1990, Clinical Microbiology Reviews.
[69] Robert Johnson,et al. Structural Analysis , 2020, Multiphysics Modeling with Application to Biomedical Engineering.
[70] L. Simpson. Molecular pharmacology of botulinum toxin and tetanus toxin. , 1986, Annual review of pharmacology and toxicology.
[71] G. Sakaguchi. Clostridium botulinum toxins. , 1982, Pharmacology & therapeutics.
[72] F. J. Bourne. The Mucosal Immune System , 1981, Current Topics in Veterinary Medicine and Animal Science.